Skip to content

Study · Randomized controlled trial · n = 1,512 · 2019

7 results

EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.

Mora PF, Chao J, Saremi A, Dex TA, Roberts M, Umpierrez GE

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists26 Jun 2019

PMID31241362 (opens in a new tab)DOI10.4158/ep-2018-0615 (opens in a new tab)PepBankPUB-31241362
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Hispanic and non-Hispanic white patients with diabetes, iGlarLixi reduced A1C more than insulin glargine.

    In plain wordsIn both ethnic groups with diabetes, iGlarLixi reduced A1C more than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseA1C reduction by ethnicity
    Study

    n = 1,512

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with iGlar, iGlarLixi resulted in greater reductions in glycated hemoglobin (A1C) and 2-hour postprandial glucose and a higher proportion of patients at target A1C <7.0% (<53 mmol/mol), regardless of ethnicity.
    2 context sentences
    Summary · context
    The efficacy and safety of insulin glargine 100 units/mL (iGlar) and the fixed-ratio combination of iGlar and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi) was assessed in Hispanic and NHW patients with T2D from 25 countries.
    Summary · context
    In this post hoc analysis, data from two 30-week randomized controlled trials comparing iGlar and iGlarLixi in patients with T2D uncontrolled on basal insulin ± oral antidiabetes drugs (OADs; LixiLan-L: NCT02058160) or uncontrolled on metformin ± OADs (LixiLan-O: NCT02058147) were evaluated.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In both ethnic groups with diabetes, iGlarLixi reduced 2-hour postprandial glucose more than insulin glargine.

    In plain wordsIn both ethnic groups, iGlarLixi reduced glucose after meals more than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glucose by ethnicity
    Study

    n = 1,512

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with iGlar, iGlarLixi resulted in greater reductions in glycated hemoglobin (A1C) and 2-hour postprandial glucose and a higher proportion of patients at target A1C <7.0% (<53 mmol/mol), regardless of ethnicity.
    2 context sentences
    Summary · context
    The efficacy and safety of insulin glargine 100 units/mL (iGlar) and the fixed-ratio combination of iGlar and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi) was assessed in Hispanic and NHW patients with T2D from 25 countries.
    Summary · context
    In this post hoc analysis, data from two 30-week randomized controlled trials comparing iGlar and iGlarLixi in patients with T2D uncontrolled on basal insulin ± oral antidiabetes drugs (OADs; LixiLan-L: NCT02058160) or uncontrolled on metformin ± OADs (LixiLan-O: NCT02058147) were evaluated.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In both ethnic groups with diabetes, more patients reached A1C <7.0% with iGlarLixi than insulin glargine.

    In plain wordsIn both ethnic groups, more patients reached the A1C target with iGlarLixi than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseA1C target attainment by ethnicity
    Study

    n = 1,512

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with iGlar, iGlarLixi resulted in greater reductions in glycated hemoglobin (A1C) and 2-hour postprandial glucose and a higher proportion of patients at target A1C <7.0% (<53 mmol/mol), regardless of ethnicity.
    2 context sentences
    Summary · context
    The efficacy and safety of insulin glargine 100 units/mL (iGlar) and the fixed-ratio combination of iGlar and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi) was assessed in Hispanic and NHW patients with T2D from 25 countries.
    Summary · context
    In this post hoc analysis, data from two 30-week randomized controlled trials comparing iGlar and iGlarLixi in patients with T2D uncontrolled on basal insulin ± oral antidiabetes drugs (OADs; LixiLan-L: NCT02058160) or uncontrolled on metformin ± OADs (LixiLan-O: NCT02058147) were evaluated.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In both trials and ethnic groups, more patients reached target A1C without hypoglycemia with iGlarLixi than insulin glargine.

    In plain wordsIn both ethnic groups, more patients reached target A1C without low blood sugar with iGlarLixi than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseA1C target without hypoglycemia
    Study

    n = 1,512

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Nevertheless, in both trials, a greater proportion of patients taking iGlarLixi than iGlar reached the composite efficacy endpoints of target A1C without hypoglycemia and target A1C without weight gain, regardless of ethnicity.
    2 context sentences
    Summary · context
    The efficacy and safety of insulin glargine 100 units/mL (iGlar) and the fixed-ratio combination of iGlar and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi) was assessed in Hispanic and NHW patients with T2D from 25 countries.
    Summary · context
    In this post hoc analysis, data from two 30-week randomized controlled trials comparing iGlar and iGlarLixi in patients with T2D uncontrolled on basal insulin ± oral antidiabetes drugs (OADs; LixiLan-L: NCT02058160) or uncontrolled on metformin ± OADs (LixiLan-O: NCT02058147) were evaluated.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In both trials and ethnic groups, more patients reached target A1C without weight gain with iGlarLixi than insulin glargine.

    In plain wordsIn both ethnic groups, more patients reached target A1C without weight gain with iGlarLixi than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseA1C target without weight gain
    Study

    n = 1,512

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Nevertheless, in both trials, a greater proportion of patients taking iGlarLixi than iGlar reached the composite efficacy endpoints of target A1C without hypoglycemia and target A1C without weight gain, regardless of ethnicity.
    2 context sentences
    Summary · context
    The efficacy and safety of insulin glargine 100 units/mL (iGlar) and the fixed-ratio combination of iGlar and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi) was assessed in Hispanic and NHW patients with T2D from 25 countries.
    Summary · context
    In this post hoc analysis, data from two 30-week randomized controlled trials comparing iGlar and iGlarLixi in patients with T2D uncontrolled on basal insulin ± oral antidiabetes drugs (OADs; LixiLan-L: NCT02058160) or uncontrolled on metformin ± OADs (LixiLan-O: NCT02058147) were evaluated.
  6. 06HumanRandomized controlled trialSafety outcome

    In non-Hispanic whites in LixiLan-L, symptomatic hypoglycemia rates were numerically lower with iGlarLixi than insulin glargine (P = .06).

    In plain wordsIn non-Hispanic whites, low blood sugar rates were numerically lower with iGlarLixi than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseSymptomatic hypoglycemia in non-Hispanic whites
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Among NHWs from the LixiLan-L trial, documented symptomatic hypoglycemia (plasma glucose ≤70 mg/dL) rates were higher with iGlar compared with iGlarLixi (P = .06), whereas this trend was reversed among Hispanics (P = .07).
    2 context sentences
    Summary · context
    The efficacy and safety of insulin glargine 100 units/mL (iGlar) and the fixed-ratio combination of iGlar and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi) was assessed in Hispanic and NHW patients with T2D from 25 countries.
    Summary · context
    In this post hoc analysis, data from two 30-week randomized controlled trials comparing iGlar and iGlarLixi in patients with T2D uncontrolled on basal insulin ± oral antidiabetes drugs (OADs; LixiLan-L: NCT02058160) or uncontrolled on metformin ± OADs (LixiLan-O: NCT02058147) were evaluated.
  7. 07HumanRandomized controlled trialSafety outcome

    In Hispanics in LixiLan-L, symptomatic hypoglycemia rates were numerically higher with iGlarLixi than insulin glargine (P = .07).

    In plain wordsIn Hispanics, low blood sugar rates were numerically higher with iGlarLixi than insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseSymptomatic hypoglycemia in Hispanics
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Source sentences

    Summary
    Among NHWs from the LixiLan-L trial, documented symptomatic hypoglycemia (plasma glucose ≤70 mg/dL) rates were higher with iGlar compared with iGlarLixi (P = .06), whereas this trend was reversed among Hispanics (P = .07).
    2 context sentences
    Summary · context
    The efficacy and safety of insulin glargine 100 units/mL (iGlar) and the fixed-ratio combination of iGlar and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi) was assessed in Hispanic and NHW patients with T2D from 25 countries.
    Summary · context
    In this post hoc analysis, data from two 30-week randomized controlled trials comparing iGlar and iGlarLixi in patients with T2D uncontrolled on basal insulin ± oral antidiabetes drugs (OADs; LixiLan-L: NCT02058160) or uncontrolled on metformin ± OADs (LixiLan-O: NCT02058147) were evaluated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.